Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide

SIMPLE SUMMARY: Glioblastoma (GBM) resistance to standard treatment is driven by stem-like cell behavior and epithelial-like-mesenchymal transition. The main purpose of this paper was to functionally validate a novel discovered pharmacological strategy to treat GBM, the dual mTOR pathway inhibitor R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Vargas-Toscano, Andres, Nickel, Ann-Christin, Li, Guanzhang, Kamp, Marcel Alexander, Muhammad, Sajjad, Leprivier, Gabriel, Fritsche, Ellen, Barker, Roger A., Sabel, Michael, Steiger, Hans-Jakob, Zhang, Wei, Hänggi, Daniel, Kahlert, Ulf Dietrich
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7766508/
https://ncbi.nlm.nih.gov/pubmed/33371210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123859
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados